Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Wait — supporting gate not met yet. Price is at or below entry $299.13 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.8): -1.5; Negative momentum.
Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in net product revenues in 2025. AMVUTTRA (vutrisiran) is the dominant revenue driver following its cardiomyopathy approval in March 2025; the company also earns... Read more
Wait — supporting gate not met yet. Price is at or below entry $299.13 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.8): -1.5; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.50, quality 8.1/10, growth 10.0/10). Score 6.4/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Alnylam Pharmaceuticals, Inc.
Latest news
- Alnylam (ALNY) Q1 earnings preview: What you should know beyond the headline estimates - MSN — MSN neutral
- Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- ALNY Earnings Preview: Alnylam Q1 2026 on April 30 - Meyka — Meyka neutral
- Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - inkl — inkl positive
- Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - Inkl — Inkl positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $299.13 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.8): -1.5; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.50, quality 8.1/10, growth 10.0/10). Target $402.13 (+36.4%), stop $279.90 (−5.3%), Setup A.R:R 8.5:1. Score 6.4/10, moderate confidence.
Take-profit target: $402.13 (+39.1% upside). Target $402.13 (+36.4%), stop $279.90 (−5.3%), Setup A.R:R 8.5:1. Stop-loss: $279.90.
Leverage penalty (D/E 2.8): -1.5; Negative momentum; Below 200-day MA.
Alnylam Pharmaceuticals, Inc. trades at a P/E of 74.1 (forward 20.8). TrendMatrix value score: 5.7/10. Verdict: Buy (Wait for Entry).
36 analysts cover ALNY with a consensus score of 3.9/5. Average price target: $447.
What does Alnylam Pharmaceuticals, Inc. do?Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in...
Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in net product revenues in 2025. AMVUTTRA (vutrisiran) is the dominant revenue driver following its cardiomyopathy approval in March 2025; the company also earns collaboration royalties from Novartis (Leqvio) and Sanofi (Qfitlia).